HOME >> BIOLOGY >> NEWS
Although controversial, stem cell therapies exhibit potential in biotechnology markets

SAN ANTONIO June 11, 2002 Stem cells have enormous potential for repairing damage to the body caused by disease, injury, or aging. When introduced into an injured area of a patient, a stem cell could survive and repopulate the region with different types of cells, forming normal tissue.

Stem cells also offer the prospect of treating many inherited diseases caused
by a single, defective gene. Though other
treatments are available, such as gene therapy,
the longevity of benefits from stem cell treatment
provides a tantalizing option for researchers.

Heated controversy has arisen over the ethics of using embryonic stem cells, extracted from either very early embryos or fetuses. The United States has now limited stem cell use to a relatively small number of existing cell lines.

Stem cells are pluripotent, possessing the ability to differentiate into other types of cells. However, other stem cells, which are not derived from embryos and not completely pluripotent, have great potential to differentiate into cells, redeveloping certain tissues or organs. Hematopoietic cells, found in the bone marrow and umbilical cord, for example, can differentiate into all types of blood cells.

In order to make stem cell therapy a reality, it is not only necessary to have suitable stem cells, but also to know how to direct their differentiation and formation of new tissues. Scientists have begun to make new discoveries concerning genes and their protein products that govern various types of cell differentiation, but additional research is imperative.

Stem cell therapies are inherently more complicated than drug treatment, providing a stumbling block for stem cell therapy in the marketplace. However, while stem cell therapy remains costly, it will almost certainly last for several years before the procedure must be repeated. A low annual cost of $2500 per patient for stem cell therapy products at the manufacturers l
'"/>

Contact: Julia Rowell
jrowell@frost.com
210-247-3870
Technical Insights
12-Jun-2002


Page: 1 2

Related biology news :

1. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
2. Serotonin metabolites in mollusks suggest pathways for human therapies
3. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies
4. Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
5. Insight into transplant rejection might lead to novel prevention therapies
6. Scientists find second way to kill cancer cells: Discovery opens possibilities for new therapies
7. Insights on stroke from the peripheral blood suggest ways to develop markers and therapies
8. Novel approaches to current cellular therapies continue progress toward disease prevention
9. Novel therapies show promise against myeloid leukemia
10. Scientists discover potential approaches to enhance existing cancer therapies
11. Clock cells, tumor suicide, tailored therapies among subjects of AACR-NCI-EORTC Conference

Post Your Comments:
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: